Guggenheim raises Tempus AI stock price target to $95 on oncology AI model

Guggenheim raised its price target for Tempus AI Inc (TEM) to $95 from $80, maintaining a Buy rating, after gaining a better understanding of the company's "highly differentiated" oncology foundation model developed in partnership with AstraZeneca and Pathos AI. This positive outlook is further supported by Tempus AI's recent FDA 510(k) clearance for its RNA-based Tempus xR IVD device and an updated Tempus Pixel cardiac imaging platform, leading H.C. Wainwright to also increase its price target to $98, although Stifel reiterated a Hold rating with a $65 target.

Analysis

Tempus AI (TEM) is exhibiting strong positive momentum, driven by favorable analyst actions and significant regulatory achievements. Guggenheim raised its price target on the stock to $95.00 from $80.00, maintaining a Buy rating, after gaining deeper conviction in the company's "highly differentiated" oncology foundation model developed with AstraZeneca. This bullish sentiment is reinforced by H.C. Wainwright, which lifted its price target to $98.00. These upgrades are supported by tangible progress in Tempus AI's product pipeline, including recent FDA 510(k) clearance for its RNA-based Tempus xR IVD device and clearance for its updated Tempus Pixel cardiac imaging platform. These developments signal validation of the company's innovation in AI-powered precision medicine. However, a degree of caution is warranted, as Stifel reiterated its Hold rating with a $65.00 price target, specifically noting the "ongoing reimbursement ramp" for the company's xT comprehensive genomic profiling test as a key factor to monitor.

Key Decisions for Investors

• Investors with a bullish outlook on AI in precision medicine could view the recent analyst upgrades and FDA clearances as a strong validation of Tempus AI's strategy and technological differentiation.
• It is crucial to monitor the progress of the reimbursement ramp for the company's xT genomic profiling test, as noted by Stifel, as this remains a key variable that could temper near-term performance and profitability.
• Given the wide dispersion in analyst price targets, ranging from $60 to $98, investors should be prepared for potential stock volatility and evaluate their own risk tolerance relative to the current price.